Dual agonists, like Survodutide and Tirzepatide, target two metabolic pathways simultaneously, offering potentially greater efficacy in treating conditions like MASH compared to single-target GLP-1 agonists, which focus on just one pathway
This emphasis on composition, not just weight, fuels lasting health
[DOI] [PMC free article] [PubMed] [Google Scholar] 42.Ding X, Saxena NK, Lin S, Gupta NA, Gupta N, Anania FA
This inflammation contributes to insulin resistance, cardiovascular damage, joint deterioration, cognitive impairment, and accelerated aging
This trend aligns with national dispensing patterns, where a study reported a nearly 600% increase in GLP-1 RA prescription fills among adolescents and young adults from 2020 to 2023 ( 9 ) and our own research, which has shown that GLP-1 RAs now make up over 5% of all prescriptions prescribed